ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Investigating the Mechanisms of Bisdemethoxycurcumin in Ulcerative Colitis: Network Pharmacology and Experimental Verification

Wu, Huihuan; Tu, Sha; Zhuo, Zewei; Jiang, Rui; Zeng, Ruijie; Yang, Qi; Lian, Qizhou*; Sha, Weihong*; Chen, Hao*广东省人民医院
MOLECULES2023-1DOI: 10.3390/molecules28010068
6阅读
引用收藏
分享

摘要

Ulcerative colitis is a chronic inflammatory bowel disorder that is hard to cure once diagnosed. Bisdemethoxycurcumin has shown positive effects on inflammatory diseases. However, the underlying bioactive interaction between bisdemethoxycurcumin and ulcerative colitis is unclear. The objective of this study was to determine the core target and potential mechanism of action of bisdemethoxycurcumin as a therapy for ulcerative colitis. The public databases were used to identify potential targets for bisdemethoxycurcumin and ulcerative colitis. To investigate the potential mechanisms, the protein-protein interaction network, gene ontology analysis, and Kyoto encyclopedia of genes and genomes analysis have been carried out. Subsequently, experimental verification was conducted to confirm the findings. A total of 132 intersecting genes of bisdemethoxycurcumin, as well as ulcerative coli-tis-related targets, were obtained. SRC, EGFR, AKT1, and PIK3R1 were the targets of highest potential, and the PI3K/Akt and MAPK pathways may be essential for the treatment of ulcerative colitis by bisdemethoxycurcumin. Molecular docking demonstrated that bisdemethoxycurcumin combined well with SRC, EGFR, PIK3R1, and AKT1. Moreover, the in vitro experiments suggested that bisdemethoxycurcumin might reduce LPS-induced pro-inflammatory cytokines levels in RAW264.7 cells by suppressing PI3K/Akt and MAPK pathways. Our study provided a comprehensive overview of the potential targets and molecular mechanism of bisdemethoxycurcumin against ulcerative colitis. Furthermore, it also provided a theoretical basis for the clinical treatment of ulcerative colitis, as well as compelling evidence for further study on the mechanism of bisdemethoxycurcumin in the treatment of ulcerative colitis.

学科与关键词

关键词
bisdemethoxycurcuminulcerative colitisnetwork pharmacologyPI3kAKT pathwayMAPK pathway
相关
加载中…
  • Bioactive Components and Potential Mechanism Prediction of Kui Jie Kang against Ulcerative Colitis via Systematic Pharmacology and UPLC-QE-MS Analysis
    He, Jinbiao; Wan, Chunping; Li, Xiaosi; Zhang, Zishu; Yang, Yu; Wang, Huaning; Qi, Yan*Evidence-based Complementary and Alternative Medicine, 2022, 2022: 9122315.被引 1
  • Therapeutic targets and pharmacological mechanisms of Coptidis Rhizoma against ulcerative colitis: Findings of system pharmacology and bioinformatics analysis
    Yang, Yuanming; Hua, Yiwei; Chen, Weihuan; Zheng, Huan; Wu, Haomeng; Qin, Shumin*; Huang, Shaogang*Frontiers in Pharmacology, 2022, 13: 1037856.被引 4
  • Efficacy of active ingredients in Qingdai (Indigo Naturalis) on ulcerative colitis: a network pharmacology-based evaluation
    Li, Yue; Wen, Shuting; Zhao, Runyuan; Fan, Dongmei; Zhao, Dike; Liu, Fengbin; Mi, Hong*Journal of Traditional Chinese Medicine, 2023, 43(1): 124-133.
查看全部 →

发表信息

论文状态
公开发表
期刊
MOLECULES
发表日期
2023-01
卷期
第 28 卷, 第 1 期
页码
68
DOI
10.3390/molecules28010068
语言
ENGLISH
成果收录
SCIE

作者

  • W

    Wu, Huihuan (第一作者)

    guangdong prov peoples hosp

  • T

    Tu, Sha

    guangdong prov peoples hosp

查看全部 9 位作者收起作者
  • Z

    Zhuo, Zewei

    guangdong prov peoples hosp

  • J

    Jiang, Rui

  • Z

    Zeng, Ruijie

    guangdong prov peoples hosp

  • Y

    Yang, Qi

    guangdong prov peoples hosp

  • L

    Lian, Qizhou (通讯)

  • S

    Sha, Weihong (通讯)

    guangdong prov peoples hosp

  • C

    Chen, Hao (通讯)

    guangdong prov peoples hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417